Pharmaceutical

MediLink and Roche partner on cancer drug development

MediLink Therapeutics has signed a global partnership and licence deal with Roche to develop YL211 for solid tumours.

Jan 3, 2024 - 18:00
MediLink and Roche partner on cancer drug development
MediLink Therapeutics has signed a global partnership and licence deal with Roche to develop YL211 for solid tumours.
Read the original article

Tags:

Previous Article

EMA validates BMS’s repotrectinib application to treat cancer

Next Article

PDS-01ADC by PDS Biotechnology for Colorectal Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Appeals court allows access to abortion pill, but with restrictions; FDA official intervened on behalf of Sarepta gene therapy

STAT+: Pharmalittle: Appeals court allows access to abo...

Apr 13, 2023

STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish

STAT+: Pharmalittle: Bluebird claims big insurer will c...

Dec 15, 2023

Pieris Pharma lays off 70% of workforce amid company restructuring

Pieris Pharma lays off 70% of workforce amid company re...

Jul 19, 2023